ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
January 26 2024 - 4:08PM
Business Wire
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) and healthy aging
research, today announced that its Chief Executive Officer, Rob
Fried, and Chief Financial Officer, Brianna Gerber, will be
participating in the Lytham Partners 2024 Investor Select
Conference.
Mr. Fried and Mrs. Gerber will participate in virtual one-on-one
meetings throughout the event on Thursday, February 1, 2024.
To arrange a meeting with the ChromaDex management team, please
contact Lytham Partners at 1x1@lythampartners.com or register for
the event at https://lythampartners.com/select2024invreg/.
For additional information on ChromaDex, visit
www.chromadex.com, and for details on investor relations, please
visit www.investors.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240126139680/en/
ChromaDex Media Contact: Kendall Knysch, Head of Public
Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024